X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs BIOCON LTD - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA BIOCON LTD ASTRAZENECA PHARMA/
BIOCON LTD
 
P/E (TTM) x 94.8 36.6 258.8% View Chart
P/BV x 13.5 4.9 277.3% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ASTRAZENECA PHARMA   BIOCON LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
BIOCON LTD
Mar-16
ASTRAZENECA PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,285496 259.2%   
Low Rs634397 159.9%   
Sales per share (Unadj.) Rs189.6174.3 108.8%  
Earnings per share (Unadj.) Rs-0.244.8 -0.5%  
Cash flow per share (Unadj.) Rs3.856.9 6.8%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs68.6202.8 33.8%  
Shares outstanding (eoy) m25.00200.00 12.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.6 197.7%   
Avg P/E ratio x-4,712.710.0 -47,332.7%  
P/CF ratio (eoy) x249.67.8 3,184.6%  
Price / Book Value ratio x14.02.2 635.4%  
Dividend payout %011.2 0.0%   
Avg Mkt Cap Rs m23,98889,220 26.9%   
No. of employees `0001.64.4 35.3%   
Total wages/salary Rs m1,6056,363 25.2%   
Avg. sales/employee Rs Th3,040.27,894.5 38.5%   
Avg. wages/employee Rs Th1,029.21,441.2 71.4%   
Avg. net profit/employee Rs Th-3.32,029.7 -0.2%   
INCOME DATA
Net Sales Rs m4,74034,854 13.6%  
Other income Rs m92845 10.9%   
Total revenues Rs m4,83235,699 13.5%   
Gross profit Rs m-1308,200 -1.6%  
Depreciation Rs m1012,423 4.2%   
Interest Rs m0102 0.0%   
Profit before tax Rs m-1396,520 -2.1%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1395,754 2.4%   
Tax Rs m52,569 0.2%   
Profit after tax Rs m-58,961 -0.1%  
Gross profit margin %-2.723.5 -11.6%  
Effective tax rate %-3.739.4 -9.3%   
Net profit margin %-0.125.7 -0.4%  
BALANCE SHEET DATA
Current assets Rs m2,72639,932 6.8%   
Current liabilities Rs m2,43516,276 15.0%   
Net working cap to sales %6.167.9 9.1%  
Current ratio x1.12.5 45.6%  
Inventory Days Days7454 137.7%  
Debtors Days Days4186 47.3%  
Net fixed assets Rs m1,03539,101 2.6%   
Share capital Rs m501,000 5.0%   
"Free" reserves Rs m94238,591 2.4%   
Net worth Rs m1,71640,556 4.2%   
Long term debt Rs m020,724 0.0%   
Total assets Rs m4,15684,816 4.9%  
Interest coverage xNM64.9-  
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.10.4 277.5%   
Return on assets %-0.110.7 -1.1%  
Return on equity %-0.322.1 -1.3%  
Return on capital %019.0 0.0%  
Exports to sales %5.730.7 18.5%   
Imports to sales %6.520.4 31.7%   
Exports (fob) Rs m27010,717 2.5%   
Imports (cif) Rs m3067,105 4.3%   
Fx inflow Rs m37511,789 3.2%   
Fx outflow Rs m4708,393 5.6%   
Net fx Rs m-963,396 -2.8%   
CASH FLOW
From Operations Rs m-85,264 -0.2%  
From Investments Rs m-146-9,540 1.5%  
From Financial Activity Rs m86210,867 7.9%  
Net Cashflow Rs m7096,591 10.7%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 0.3 8.4 3.6%  
FIIs % 15.7 10.7 146.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.9 45.7%  
Shareholders   12,856 109,995 11.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  TORRENT PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS